Allogeneic hemopoietic stem cell transplantation for patients with myelofibrosis

Author: Hai-xiao ZHANG ¹ ; Er-lie JIANG ¹
Author Information

1. Hematology Department of Chinese Academy of Medical Sciences and Peking Union Medical College Tianjin 300020, China
Publication Type:Journal Article
Keywords: myelofibrosis; allogeneic hemopoietic stem cell transpantation; ruxolitinib
From: Chinese Journal of Practical Internal Medicine 2019;39(02):139-142
CountryChina
Language:Chinese
Abstract: Allogeneic hematopoietic stem cell transplantation(allo-HSCT) is the only therapy to cure myelofibrosis(MF) at present. This article gives a review on the following problems: who needs allo-SCT, how to choose allo-SCT in the era of ruxolitinib, the role of Ruxolitinib in the transplantation, whether allo-SCT can cure MF, and how to improve the effect of allo-SCT to guide the allo-SCT, in order for MF patients in clinical work.